Vigilex Xendo DeutschlandXendo Deutschland

Welcome to the Xendo website

Xendo is a leading, independent consultancy and project management organization in the life sciences, pharmaceutical and healthcare fields. Our ambition is to enhance the quality and safety of medicine and help shorten the time to market for drugs and medical devices that improve the quality of life.

For over 20 years we have supported hundreds of clients in more than 25 countries worldwide. For further information please contact us at info@xendo.com. Or just click one of the buttons to find out what Xendo can do in your area of expertise.

Business Relocation

I hereby would like to inform you that Xendo has relocated as of January 4th to our new and larger office.

 

Our new visiting address is:

 

Schipholweg 73 – 75

2316 ZL Leiden

Netherlands, The

 

Our postal address and phone number will remain the same:

 

PO Box 255

2300 AG Leiden

T: 071 524 40 00


XENDO PREMIUM SPONSOR: INNOVATION FOR HEALTH - SHAPING THE FUTURE OF HEALTHCARE TOGETHER! 

After two successful editions, Innovation for Health is back on February 18th, 2016 in WTC Rotterdam, the Netherlands. With more than 800 delegates, over 50 influential speakers, many one-on-one meetings, innovation pitches, poster presentations, an interactive expo and much more, Innovation for Health 2016 will be a great place to catch up on the latest trends, to exchange ideas with leading innovators, to identify new opportunities for collaboration and to get inspired by the developments in Healthcare & Life Sciences. For registration and more information, visit www.innovationforhealth.eu! Come and meet Xendo there. 

As Premium sponsor of Innovation for Health we offer our relations the possibility to receive a discount on the registration fee to participate in this premier conference on February 18th, 2016 in WTC Rotterdam.

Register on www.innovationforhealth.eu and use the voucher code XE20160218 to receive €50 discount on the registration fee.

GMP FOR EXCIPIENTS:
MANUFACTURING AUTHORIZATION
HOLDERS EXPECTED TO TAKE ACTION

Following guideline 2015/C 95/02 of March 19, 2015, manufacturing authorization holders are required to perform a formalized risk assessment to establish the appropriate GMP for excipients used in medicines for human use.

The risks associated with the source and application of the excipients should be analyzed and used to define which elements of GMP are expected to be in place to control the quality of the excipients. Secondly, the level of GMP of the excipient manufacturers should be assessed and appropriate risk management should be implemented to control any gaps. A program to monitor and control the performance of the excipient manufacturers will need to be set up as part of the quality management system. ....read more